SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for completio

SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

AND PROVIDES BUSINESS UPDATE

Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018

AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019

Molgradex Phase 2a OPTIMA study enrollment on track for completion in Q3 2018

First patient enrolled in Molgradex IMPALA-X safety extension study

Conference call scheduled for today at 5:30 p.m. E.T.

AUSTIN, TX May 9, 2018 - Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today reported financial results for the first

quarter ended March 31, 2018 and provided a business update.

It has been an incredibly productive quarter, including the launch of two new

clinical studies, OPTIMA and IMPALA-X, with our lead product candidate Molgradex, stated Rob Neville, chief executive officer of Savara. With a total of four ongoing clinical studies, our focus for the remainder of the year

will continue to be the advancement of our core programs, while actively exploring the further expansion of our pipeline.

and Recent Developments

First Quarter Financial Results

Savara s net loss attributable to common shareholders for the three months ended March 31, 2018 was $26.8 million, or $(0.88) per share,

compared with a net loss attributable to common shareholders of $5.0 million, or $(1.65) per share, for the first quarter of 2017, which represents the historical financial information of the private company Savara Inc., which completed

its merger transaction with Mast Therapeutics, Inc. on April 27, 2017 (the Merger ).

Research and development expenses were $8.5 million for the three months ended March 31, 2018,

compared with $2.9 million for the first quarter of 2017. The increase was primarily due to $2.7 million in increased expenses associated with the development of Molgradex, including the expansion of the IMPALA study in the U.S. and

other countries and the commencement of the Molgradex NTM study, an increase of $2.2 million in AeroVanc study costs related to Phase 3 activities, and $0.7 million related to non-recurring milestone payments relating to the Aironite study acquired

in the Merger, which was not a part of our product pipeline in the first quarter of 2017.

General and administrative expenses for the three months ended

March 31, 2018 were $1.8 million, compared with $1.7 million for the first quarter of 2017.

Also, during the three months ended March 31, 2018,

we recognized a one-time noncash impairment charge of $21.7 million to the carrying value of IPR&D related to the Aironite product candidate assumed in the Merger due to the unfavorable results from a Phase 2 study in which Aironite failed to

meet the endpoints of the study and showed limited effectiveness in patients. We do not intend to further support or pursue the development of Aironite.

We reported a $4.6 million tax benefit for the first quarter of 2018 related to the reversal of a deferred tax liability resulting from the impairment of

IPR&D acquired in the Merger.

As of March 31, 2018, Savara had cash, cash equivalents and short-term investments

of approximately $85.0 million. The company s operating expenses for the first quarter of 2018 were approximately $32.1 million which included the one-time noncash impairment charge of $21.7 million to the carrying value of

IPR&D acquired in the Merger. Savara ended the first quarter of 2018 with approximately $14.9 million in debt.

Savara will hold a conference call today beginning at 5:30 p.m. Eastern Time / 4:30 p.m. Central Time to provide a

business update. Shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and should

request the Savara Inc. call. A live webcast of the conference call will be available online from the Investors section of Savara s website at http://www.savarapharma.com/investors/events/. Replays of the webcast will be available

on Savara s website for 30 days and a telephone replay will be available through May 16th, 2018 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada, and

(412) 317-0088 from elsewhere outside the U.S. by entering replay access code 10119917.

Savara Inc. is an orphan lung disease company. Savara s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or

GM-CSF, in Phase 3 development for aPAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara s strategy involves expanding its pipeline

of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara s management team has significant experience in

orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at

www.savarapharma.com. (Twitter: @SavaraPharma)

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as expect, intend, plan,

anticipate, believe, and will, among others. Such statements include, but are not limited to, statements relating to our focus for the remainder of the year being on the continued advancement of our core programs

and actively exploring further expansion of our pipeline, the timing of topline data or interim results and completion of enrollment of our Molgradex Phase 3 IMPALA, AeroVanc Phase 3 AVAIL and Molgradex Phase 2a OPTIMA studies, our plans to initiate

the IMPALA-X study in 12 of the countries participating in the IMPALA study by the end of 2018, and our strategy and our goals. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not

place undue reliance on these forward-looking statements. Because such statements are subject to risks and

uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara s current

expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and

uncertainties, which include, without limitation, risks and uncertainties associated with the outcome of our ongoing clinical trials for our product candidates, the ability to project future cash utilization and reserves needed for contingent future

liabilities and business operations, the availability of sufficient resources for Savara s operations and to conduct or continue planned clinical development programs, the ability to obtain the necessary patient enrollment for our product

candidates in a timely manner, the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex and AeroVanc that

are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional equity capital if needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these

cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue

reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were

made, except as may be required by law.

Ioana C. Hone (ir@savarapharma.com)

For IR: Solebury Trout

Gitanjali Jain Ogawa (Gogawa@troutgroup.com)

For Media: Neon Interactive

(patrick@neoninteractive.com)

Savara Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

Savara Inc. and Subsidiaries